Cytokinetics Inc’s recently made public that its EVP Research & Development Malik Fady Ibraham unloaded Company’s shares for reported $72680.0 on Aug 05 ’25. In the deal valued at $36.34 per share,2,000 shares were sold. As a result of this transaction, Malik Fady Ibraham now holds 140,610 shares worth roughly $4.8 million.
Then, Blum Robert I sold 5,000 shares, generating $182,250 in total proceeds. Upon selling the shares at $36.45, the President & CEO now owns 388,108 shares.
Before that, Malik Fady Ibraham sold 2,000 shares. Cytokinetics Inc shares valued at $74,940 were divested by the EVP Research & Development at a price of $37.47 per share. As a result of the transaction, Malik Fady Ibraham now holds 140,610 shares, worth roughly $4.8 million.
A number of analysts have revised their coverage, including Barclays’s analysts, who began to cover the stock in late April with a ‘”an Overweight”‘ rating. Citigroup began covering CYTK with “Buy” recommendation on February 07, 2025. Stifel started covering the stock on January 22, 2025. It rated CYTK as “a Buy”.
Price Performance Review of CYTK
On Friday, Cytokinetics Inc [NASDAQ:CYTK] saw its stock fall -3.23% to $34.11. Over the last five days, the stock has lost -7.03%. Cytokinetics Inc shares have fallen nearly -36.29% since the year began. Nevertheless, the stocks have fallen -27.49% over the past one year.
How much short interest is there in Cytokinetics Inc?
A steep rise in short interest was recorded in Cytokinetics Inc stocks on 2025-07-15, growing by 1.92 million shares to a total of 15.93 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 14.01 million shares. There was a rise of 12.08%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on November 08, 2024 when RBC Capital Mkts began covering the stock and recommended ‘”an Outperform”‘ rating along with a $80 price target.
